Welcome to our dedicated page for GNHAY news (Ticker: GNHAY), a resource for investors and traders seeking the latest updates and insights on GNHAY stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect GNHAY's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of GNHAY's position in the market.
Vifor Pharma announced the appointment of Hervé Gisserot as Chief Commercial Officer, effective January 17, 2022. Gisserot, formerly of GlaxoSmithKline, brings extensive experience in commercial leadership across various regions, focusing on sales, marketing, and market access. Under his leadership, various commercial roles will report directly to him, enhancing commercial execution. This aligns with plans to launch four pipeline products within the next 18 months, aiming to maximize the company's iron portfolio.
Angion Biomedica Corp. (NASDAQ: ANGN) and Vifor Pharma announced results from the Phase-II GUARD trial of ANG-3777, aimed at preventing acute kidney injury (AKI) during cardiac surgery. The trial did not achieve its primary endpoint of reduced serum creatinine levels compared to placebo (8.4% vs. 7.3%, p=0.77). However, a secondary endpoint, MAKE90, suggested potential benefits with fewer AKI events in the ANG-3777 group (14.7% vs. 21.5%, p=0.155). The overall safety profile was consistent with prior studies. Further data analysis is ongoing to determine next steps for ANG-3777.
Vifor Pharma Group addresses market speculation regarding its growth strategies in a recent ad hoc announcement. The company is actively exploring options to enhance its market position through organic growth and potential partnerships or acquisitions. Vifor Pharma, listed on the Swiss Stock Exchange, aims to lead in areas such as iron deficiency, nephrology, and cardio-renal therapies. The statement emphasizes that discussions with other market participants are ongoing but details are not disclosed.
Vifor Pharma Group announces the retirement of Colin Bond as Chief Financial Officer, effective by the end of December 2021. The company is actively seeking a successor. CEO Abbas Hussain expressed gratitude for Bond's leadership and contributions during his tenure. Vifor Pharma, based in Switzerland, aims to lead in iron deficiency and nephrology therapies, focusing on innovative patient solutions.
Iron Deficiency Day 2021 emphasizes the importance of raising awareness about iron deficiency and anemia. Supported by Vifor Pharma and a coalition of health organizations, the initiative highlights the impact of COVID-19 on access to diagnosis and treatment. It aims to educate individuals on recognizing symptoms and seeking early medical help. With iron deficiency affecting about half of patients with chronic kidney disease and heart failure, awareness and early diagnosis are crucial. The initiative encourages individuals to take control of their health by understanding iron's role in overall well-being.
Vifor Pharma has announced its acquisition of Sanifit Therapeutics and Inositec AG, enhancing its nephrology portfolio. The acquisition amount for Sanifit includes an upfront payment of
The Committee for Medicinal Products for Human Use (CHMP) has recommended Tavneos® (avacopan) for the treatment of ANCA-associated vasculitis in Europe. This marks a significant step for Vifor Pharma, with a decision from the European Commission expected in Q1 2022. The recommendation is based on positive results from the pivotal ADVOCATE trial involving 331 patients, demonstrating superior efficacy over standard treatments. If approved, Tavneos® will be available in all EU member states, Iceland, Liechtenstein, and Norway.
Angion Biomedica Corp. (NASDAQ: ANGN) announced disappointing results from its phase-III trial of ANG-3777 for kidney transplant patients at risk for delayed graft function (DGF). The trial did not show a statistically significant difference in estimated Glomerular Filtration Rate (eGFR) compared to placebo at 12 months (53.3 vs. 50.4 mL/min/1.73m2, p=0.33). Although there were minor indications of biological activity, the data did not support an indication in DGF. Further data analysis is ongoing to determine next steps.
Vifor Pharma Group announced significant changes to its Executive Committee, with Lee Heeson and Gregory Oakes departing for personal reasons. Succession planning is already in progress. The company welcomes Molly Painter as the new President of U.S. operations, effective October 18, 2021. Painter has over 20 years of experience in healthcare and is expected to drive growth in key therapeutic areas. CEO Abbas Hussain expressed gratitude to departing leaders for their contributions, especially during the COVID-19 pandemic.
Vifor Fresenius Medical Care Renal Pharma announced that Japan's Ministry of Health and Labor Welfare has approved TAVNEOS® for treating ANCA-associated vasculitis, specifically granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). This marks TAVNEOS® as the first oral therapy for these severe autoimmune diseases. Kissei Pharmaceutical will market TAVNEOS® in Japan following National Health Insurance price listing, with approximately 10,000 patients in need of effective treatment. The approval followed positive results from the ADVOCATE phase-III trial involving 331 patients.
FAQ
What is the market cap of GNHAY (GNHAY)?
